-
Mashup Score: 3Tislelizumab, a novel anti-PD1 in hepatocellular carcinoma? Quality-of-Life, Non-Inferiority, and Duration of Treatment in RATIONALE-301. - 3 month(s) ago
Quality-of-life data should be interpreted with extra caution when censoring rates are high.
Source: www.drugdevletter.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 1The Drug Development Letter | Vinay Prasad | Substack - 3 month(s) ago
We cover all aspects of pharmaceutical drug development; early, late phase and FDA pivotal trials; Focus on oncology, but also cover important cardiology, neurology and drugs for rare diseases. Click to read The Drug Development Letter, by Vinay Prasad, a Substack publication with thousands of subscribers.
Source: www.drugdevletter.comCategories: General Medicine News, Hem/OncsTweet-
RT @pharmatinib: Check out our latest post on https://t.co/iCAC40k5ik @Timothee_MD @VPrasadMDMPH "While most discussions of the shortage c…
-
-
Mashup Score: 11Why Should a Top FDA Official Unilaterally Approve an Expensive Gene Therapy? The Case of Elevidys. - 4 month(s) ago
Peter Marks, the director of the Center for Biologics Evaluation and Research within the Food and Drug Administration (FDA), unilaterally approved Sarepta Therapeutics’ gene therapy.
Source: www.drugdevletter.comCategories: General Medicine News, Hem/OncsTweet-
Why Should a Top @US_FDA Official #PeterMarks Unilaterally Approve a $$$$$$ Gene Therapy? The Case of Elevidys. https://t.co/58VWOqo0IS via @VPrasadMDMPH & @Timothee_MD Next Q, what is his exit strategy now? Where (which pharma company) is he going to join next in his career?
-
-
Mashup Score: 26
Response Rate is a measure of anti-cancer drug activity. It’s more reliable in early phase trials than PFS estimates … yet to be analyzed with great scrutiny!
Source: www.drugdevletter.comCategories: General Medicine News, Hem/OncsTweet-
This tweet was always wrong. After we took a deep look we found major issues @Timothee_MD https://t.co/MpuN5vA8LL https://t.co/mZLnWUoPxo
-
-
Mashup Score: 29The Drug Development Letter | Vinay Prasad | Substack - 4 month(s) ago
We cover all aspects of pharmaceutical drug development; early, late phase and FDA pivotal trials; Focus on oncology, but also cover important cardiology, neurology and drugs for rare diseases. Click to read The Drug Development Letter, by Vinay Prasad, a Substack publication with thousands of subscribers.
Source: www.drugdevletter.comCategories: General Medicine News, Hem/OncsTweet-
RT @pharmatinib: Check out our latest post on https://t.co/iCAC40k5ik @Timothee_MD @VPrasadMDMPH "While most discussions of the shortage c…
-
-
Mashup Score: 20Project Orbis — harmonizing up or down? - 5 month(s) ago
By Kristina Jenei
Source: www.drugdevletter.comCategories: General Medicine News, Expert PicksTweet-
Great thread by Kristina on our new @TheLancetOncol paper She also breaks it down now in the Drug Development Letter https://t.co/B8VBvx03B0 https://t.co/mBPX7pO2Wo https://t.co/HTQyQTVNbD
-
-
Mashup Score: 60Eli Lilly's Court Victory: Dutch Agency Must Reevaluate Abemaciclib Amid Controversy - 5 month(s) ago
Eli Lilly’s court appeal to override the negative assessment of abemaciclib in the Netherlands
Source: www.drugdevletter.comCategories: General Medicine News, Hem/OncsTweet-
We have an amazing post on the Drug Development Letter Eli Lilly, like a supervillian, sued the Netherlands for not paying for their uncertain cancer drug, and they WON! Crazy precedent. Learn more. https://t.co/9CL1SeQOC9
-
-
Mashup Score: 24THEOREMM - A Novel Framework for Cancer Registration Trials - 5 month(s) ago
“Trials in HEmatology and Oncology REviewed by Metaresearch Methods”
Source: www.drugdevletter.comCategories: General Medicine News, Hem/OncsTweet-
Just out in @EJCI_News @Timothee_MD and team outline a project called THEOREMM where we assess cancer drugs in REAL TIME Check it out https://t.co/Jgl88GUyqc https://t.co/TC7JFBCIcX
-
-
Mashup Score: 24THEOREMM - A Novel Framework for Cancer Registration Trials - 5 month(s) ago
“Trials in HEmatology and Oncology REviewed by Metaresearch Methods”
Source: www.drugdevletter.comCategories: General Medicine News, Hem/OncsTweet-
Just out in @EJCI_News @Timothee_MD and team outline a project called THEOREMM where we assess cancer drugs in REAL TIME Check it out https://t.co/Jgl88GUyqc https://t.co/TC7JFBCIcX
-
-
Mashup Score: 14
Maintenance osimertinib in unresectable stage III EGFR-mutant cancer.
Source: www.drugdevletter.comCategories: General Medicine News, Hem/OncsTweet-
Should LAURA change our practice? #Osimertinib #NEJM #ASCO24 A Pro Con Debate Subscribe to the Drug Development Letter for FREE @Timothee_MD https://t.co/PKqJDxhwDi
-
Tislelizumab, a novel anti-PD1 in hepatocellular carcinoma? Quality-of-Life, Non-Inferiority, and Duration of Treatment in RATIONALE-301. Quality-of-life data should be interpreted with extra caution when censoring rates are high https://t.co/CMdOziexft via @Timothee_MD